Tarsus Pharmaceuticals (TARS) Competitors

Tarsus Pharmaceuticals (NASDAQ:TARS) and Fusion Pharmaceuticals (NASDAQ:FUSN) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their media sentiment, institutional ownership, profitability, community ranking, dividends, earnings, analyst recommendations, valuation and risk.

Does the MarketBeat Community favor TARS or FUSN?

Tarsus Pharmaceuticals received 4 more outperform votes than Fusion Pharmaceuticals when rated by MarketBeat users. Likewise, 65.22% of users gave Tarsus Pharmaceuticals an outperform vote while only 64.06% of users gave Fusion Pharmaceuticals an outperform vote.

Company	Underperform	Outperform
Tarsus Pharmaceuticals	Outperform Votes 45 65.22%	Underperform Votes 24 34.78%
Fusion Pharmaceuticals	Outperform Votes 41 64.06%	Underperform Votes 23 35.94%

Do insiders and institutionals have more ownership in TARS or FUSN?

90.0% of Tarsus Pharmaceuticals shares are held by institutional investors. Comparatively, 72.9% of Fusion Pharmaceuticals shares are held by institutional investors. 8.3% of Tarsus Pharmaceuticals shares are held by company insiders. Comparatively, 7.8% of Fusion Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Does the media favor TARS or FUSN?

In the previous week, Tarsus Pharmaceuticals had 25 more articles in the media than Fusion Pharmaceuticals. MarketBeat recorded 25 mentions for Tarsus Pharmaceuticals and 0 mentions for Fusion Pharmaceuticals. Tarsus Pharmaceuticals' average media sentiment score of 0.59 beat Fusion Pharmaceuticals' score of 0.00 indicating that Tarsus Pharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
Tarsus Pharmaceuticals	Positive
Fusion Pharmaceuticals	Neutral

Do analysts recommend TARS or FUSN?

Tarsus Pharmaceuticals currently has a consensus price target of $54.20, indicating a potential upside of 16.36%. Fusion Pharmaceuticals has a consensus price target of $20.25, indicating a potential downside of 6.03%. Given Tarsus Pharmaceuticals' stronger consensus rating and higher possible upside, research analysts plainly believe Tarsus Pharmaceuticals is more favorable than Fusion Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tarsus Pharmaceuticals	0 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	3.00
Fusion Pharmaceuticals	0 Sell rating(s)	13 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.07

Which has better earnings & valuation, TARS or FUSN?

Fusion Pharmaceuticals has lower revenue, but higher earnings than Tarsus Pharmaceuticals. Fusion Pharmaceuticals is trading at a lower price-to-earnings ratio than Tarsus Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tarsus Pharmaceuticals	$17.45M	102.05	-$135.89M	-$3.81	-12.23
Fusion Pharmaceuticals	$2.07M	885.53	-$94.90M	-$1.42	-15.18

Which has more volatility and risk, TARS or FUSN?

Tarsus Pharmaceuticals has a beta of 1, suggesting that its stock price has a similar volatility profile to the S&P 500.Comparatively, Fusion Pharmaceuticals has a beta of -0.69, suggesting that its stock price is 169% less volatile than the S&P 500.

Is TARS or FUSN more profitable?

Tarsus Pharmaceuticals has a net margin of -103.64% compared to Fusion Pharmaceuticals' net margin of -4,136.55%. Fusion Pharmaceuticals' return on equity of -48.74% beat Tarsus Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tarsus Pharmaceuticals	-103.64%	-55.86%	-39.28%
Fusion Pharmaceuticals	-4,136.55%	-48.74%	-36.87%

Summary

Tarsus Pharmaceuticals beats Fusion Pharmaceuticals on 14 of the 19 factors compared between the two stocks.